A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour System for treating long-segment (>25 cm) blockages in the femoropopliteal artery. The data were presented as a late-breaking clinical trial session at Vascular InterVentional Advances (VIVA 17), Sept. 11-14 in Las Vegas. DETOUR I trial results were presented by Sean Lyden, M.D., chairman of the department of Vascular Surgery at Cleveland Clinic.

Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack, according to a research letter published in the Journal of the American College of Cardiology.

September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, according to late-breaking results from the VIVA trial presented at the 2017 European Society of Cardiology (ESC) Congress and and published in the Lancet. The combined screening for abdominal aortic aneurysm, peripheral artery disease, and hypertension gained more living years for lower costs than European cancer screening programs.

September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in patients with high cardiovascular risk and elevated LDL cholesterol, according to late-breaking results from the ORION 1 trial presented at the 2017 European Society of Cardiology (ESC) Congress.

September 12, 2017 — Very aggressive reduction of LDL-cholesterol to ultra-low levels was associated with progressively fewer cardiovascular events and appears to pose no safety concerns in patients with stable atherosclerotic cardiovascular disease over 2.2 years of follow-up, according to a new analysis of the FOURIER Trial. The results were presented at the 2017 European Society of Cardiology (ESC) Congress and published in the Lancet.

September 12, 2017 — The IL-1β inhibitor canakinumab lowers the risk of cardiovascular disease and lung cancer risk by reducing inflammation, according to late-breaking results from the CANTOS trial presented at the 2017 European Society of Cardiology (ESC) Congress and published in the New England Journal of Medicine (NEJM).

COMPASS Trial Shows Rivaroxaban With Aspirin Improves Stable Cardiovascular Disease

September 12, 2017 — Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with stable coronary or peripheral artery disease, according to late-breaking results from the COMPASS Trial presented in a Hot Line late-breaking clinical trials session at the 2017 European Society of Cardiology (ESC) Congress and published in the New England Journal of Medicine (NEJM).

Hoag Memorial Hospital Presbyterian recently became the first hospital in Orange County, Calif., to install the Siemens Somatom Force computed tomography (CT) scanner. The Somatom Force allows radiologists to obtain higher-quality images faster, more efficiently and with less radiation than older-generation CT scanners.

Cardiovascular Research Foundation (CRF) announced the promotion of Juan F. Granada, M.D., as the foundation’s president and chief executive officer (CEO). CRF sponsors TCT.

September 12, 2017 – The Cardiovascular Research Foundation (CRF) announced the promotion of Juan F. Granada, M.D., as the foundation’s president and chief executive officer (CEO). Granada was also appointed to CRF’s Board of Directors. A renowned leader in cardiology, he joined CRF in 2007 and served as executive director and chief innovation officer at the CRF Skirball Center for Innovation. He is also an assistant professor of medicine at Columbia University College of Physicians and Surgeons. 

September 11, 2017 — According to the latest market study released by Technavio, the global electrophysiology therapeutic devices market is expected to grow at a compound annual growth rate (CAGR) of more than 9 percent between 2017 and 2021.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now